As a result of low drug resistance in pleural tuberculosis, treatment regimens of pleural TB may include fewer drugs and maintain appropriate levels of efficaciousness.
Disparities in tuberculosis rates persist by race, ethnicity, and geography.
The FDA has approved pretomanid tablets (TB Alliance) in combination with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).
The FDA has approved Sirturo (bedaquiline; Janssen) for use in pediatric patients aged 12 to less than 18 years in MDR-TB.
An association has been identified between newly diagnosed active tuberculosis, diabetes, and body mass index.
The CDC has issued 3 recommendations for mitigating a reduction in tuberculosis testing capability.
In a review update, XpertMTB/RIF was found to be sensitive and specific for diagnosing pulmonary TB and rifampicin resistance which is consistent with the last review completed in 2014.
The novel Fujifilm SILVAMP TB LAM assay offers superior diagnostic sensitivity while also maintaining specificity, compared with standard assay.